Home › Calculator › NTLA Dividend Calculator 2026
NTLA Dividend DRIP Calculator 2026
11.47% YieldHealthcareIntellia Therapeutics, Inc. · NASDAQ
Price: $17.43 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When NTLA pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your NTLA snowball 📈
$10,000 in NTLA → $19.87M in 10 years · $1,569,197.83/month
About Intellia Therapeutics, Inc. (NTLA) — Dividend Analysis 2026
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
Compare NTLA with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full NTLA DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open NTLA position with:
🌍 NTLA Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold NTLA.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 11.47% | 8.67% | $1,147 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 9.75% | 6.95% | $975 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 9.18% | 6.38% | $918 / yr |
| 🇬🇧 UK ISA | 0% | 11.47% | 8.67% | $1,147 / yr |
| 🇬🇧 UK Taxable | 8.75% | 10.47% | 7.67% | $1,047 / yr |
| 🇨🇦 TFSA | 0% | 11.47% | 8.67% | $1,147 / yr |
| 🇨🇦 CA Taxable | 25% | 8.60% | 5.80% | $860 / yr |
| 🇦🇺 Super (pension) | 15% | 9.75% | 6.95% | $975 / yr |
| 🇦🇺 AU Taxable | 30% | 8.03% | 5.23% | $803 / yr |
| 🇩🇪 DE Taxable | 26.375% | 8.44% | 5.64% | $844 / yr |
| 🇫🇷 FR Taxable | 30% | 8.03% | 5.23% | $803 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 NTLA Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 NTLA Dividend Payment Schedule
NTLA pays quarterly — 4 times per year. Next ex-div: TBD.
📊 NTLA vs Healthcare Benchmarks
How NTLA compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for NTLA sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ NTLA Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Sale | 2026-07-01 | 2,641 | $16.78 | $44.3K | ||
| Sale | 2026-07-02 | 4,677 | $18.00 | $84.2K | ||
| A-Award | 2026-06-09 | 9,200 | — | — | ||
| A-Award | 2026-06-09 | 13,300 | $12.89 | $171.4K | ||
| A-Award | 2026-06-09 | 9,200 | — | — | ||
| A-Award | 2026-06-09 | 13,300 | $12.89 | $171.4K | ||
| A-Award | 2026-06-09 | 9,200 | — | — | ||
| A-Award | 2026-06-09 | 13,300 | $12.89 | $171.4K | ||
| A-Award | 2026-06-09 | 9,200 | — | — | ||
| A-Award | 2026-06-09 | 13,300 | $12.89 | $171.4K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the NTLA dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Intellia Therapeutics, Inc. (NTLA) is currently trading at $17.43, 90% below its 52-week high. The current dividend yield is 11.47% based on an annual payout of $2.00 per share.
NTLA (Intellia Therapeutics, Inc.) — 11.47% Dividend Yield Analysis
Intellia Therapeutics, Inc. (NTLA) is a healthcare stock currently trading at $17.43 with a dividend yield of 11.47%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (11.47%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.